Immune Regulation Limited, a US and UK-based clinical-stage biotechnology company, announced on Monday that it has closed a Series B round of financing led by Boston-based Morningside Ventures, a part of Hong Kong’s Chan family-owned Morningside Group.
The Series B round saw the participation of existing shareholders including London-based 24Haymarket. The round is structured in two tranches and includes an option for Morningside to invest further capital at a step up to the initial two tranches, according to a statement.
